Company aTyr Pharma Inc Nasdaq
Equities
US0021201035
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Innovative Medicines
100.0
%
| 10 | 100.0 % | 0 | 100.0 % | -96.60% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 10 | 100.0 % | 0 | 100.0 % | -96.60% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Sanjay Shukla
CEO | Chief Executive Officer | 52 | 16-03-29 |
Jill Broadfoot
DFI | Director of Finance/CFO | 63 | 18-07-29 |
Lisa Carey
CTO | Chief Tech/Sci/R&D Officer | - | 15-05-31 |
Ashlee Dunston
IRC | Investor Relations Contact | - | 20-03-31 |
Peter Villiger
PRN | Corporate Officer/Principal | - | 16-04-30 |
Human Resources Officer | - | 21-12-23 | |
General Counsel | - | 21-10-05 | |
Leslie Nangle
PRN | Corporate Officer/Principal | - | - |
Nancy Krueger
LAW | General Counsel | 56 | 14-09-30 |
Andrew B. Cubitt
PRN | Corporate Officer/Principal | - | 11-08-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Schimmel
FOU | Founder | 83 | 05-09-07 |
Tim Coughlin
CHM | Chairman | 57 | 17-04-09 |
John Clarke
BRD | Director/Board Member | 70 | 05-08-31 |
Sara Zaknoen
BRD | Director/Board Member | 65 | 21-05-24 |
Sanjay Shukla
CEO | Chief Executive Officer | 52 | 16-03-29 |
Jane Gross
BRD | Director/Board Member | 67 | 19-06-27 |
Svetlana Lucas
BRD | Director/Board Member | 52 | 19-06-27 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 69,010,940 | 67,228,938 ( 97.42 %) | 0 | 97.42 % |
Company contact information
aTyr Pharma, Inc.
10240 Sorrento Valley Road Suite 300
92121, San Diego
+858 731 8389
http://www.atyrpharma.comSector
1st Jan change | Capi. | |
---|---|---|
+26.37% | 48.16B | |
-1.01% | 41.73B | |
+41.93% | 41.03B | |
-5.31% | 28.77B | |
+9.34% | 25.59B | |
-21.69% | 18.96B | |
+6.23% | 12.92B | |
+26.99% | 12.03B | |
-3.38% | 11.77B |